FDA has announced "Breakthrough Designation" for 3 drugs + 1 test being developed: ** Biogen: litifilimab (targets dendritic cells) for cutaneous lupus ** Novartis: Ianalumab (BAFF blockade) for Sjogrens ** J&J: Nipocaiimab (FcRn) for Sjogrens ** Encarta: pocket Lyme test https://t.co/zODOTWyqP8